HrC Cancer
Monitoring
Program
The Only Way to Beat
Cancer is to Catch it Early
HrC Cancer Monitoring Program
- Advanced HrC Genomics Technology
- Monitors for Early Indicators of Cancer
- Assesses Risk of Cancer Presence
- Identifies 'Absence' of Cancer
- 60+ Different Types of Cancer
- Accurate & Reliable Results
- Results Issued within 6/8 Weeks
- Edison Gold Award Winners 2025
The HrC Cancer Monitoring Program utilises advanced blood-based technology to identify and monitor the early indicators of cancer.
From a patient’s blood sample, we can:
- Identify if there is “no risk” of cancer presence (which also suggests a negligible risk of developing cancer within the following one year).
- Assess existing risk of cancer presence which can vary from negligible, low, moderate, to high.
A “no risk” score from indicates that the molecular markers being tracked are within the range of a healthy individual who is cancer-free, with no previous history of cancer.
Who We Can Help
Asymptomatic Patients
- Evaluate current risk of cancer presence.
- Detect early molecular or cellular changes associated with pre-symptomatic cancer development.
- Provide early molecular indicators for clinical correlation.
- Differentiate benign or malignant tumour condition from healthy population.
- Identify precancerous conditions amenable to preventive treatment. Early-stage interventions can improve therapeutic response.
- Contribute to better health economics through earlier disease detection.
- Identify high-risk population requiring close and periodic monitoring.
- Enable large-scale, population-level health surveillance.
Suitable For:
- Asymptomatic individuals seeking preventive assessment.
- Symptomatic individuals wanting to assess underlying triggers, if any.
- Individuals with a known family history of cancer.
Enjoy peace of mind through knowing that your cancer risk is being monitored on an annual basis. The only way to beat cancer is to catch it early. The only way to proactively catch cancer early is to monitor for its presence.
Cancer Patients
Monitoring Responsiveness to Treatment
- Assess therapeutic response at pre-, during-, and post-treatment stages.
- Monitor individualised treatment effectiveness.
- Enhance survival outcomes through early recognition of treatment resistance or response.
Suitable For:
- Patients currently receiving active therapy for cancer.
Cancer Survivors
Confirming Remission
Why monitor for cancer post-remission?
- Monitor remission status following completion of therapy.
- Detect early recurrence and improve post-remission survival rates.
- Identify secondary malignancies or metastatic reactivation.
- Support long-term health tracking and enhance quality of life.
Suitable For:
- Cancer survivors who have been disease-free for at least six months after treatment completion.
